Skip to main content

Advertisement

Log in

B7-H1 pathway and its role in the evasion of tumor immunity

  • Invited Review
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

B7-H1 is a recently identified member of the B7 family molecules. Upon ligation to its receptors on T cells it regulates activation and differentiation of T cells. B7-H1 preferentially costimulates IL-10 production in resting T cells and further induces the apoptosis of activated T cells. PD-1 is a receptor of B7-H1 and is shown to mediate the inhibition of activated T cell response, presumably by inhibiting cell cycle progression. The expression of B7-H1 protein is limited to macrophage lineage of cells in normal tissues, although its mRNA transcription is found in a broad range of tissues. In contrast, B7-H1 is abundant in various human cancers. The tumor-associated B7-H1 increases apoptosis of antigen specific T cells, leading to growth of immunogenic tumor growth in vivo. Current data suggest that B7-H1 regulates the organ-specific tolerance in normal tissue and may contribute to immune evasion by cancers. Selective manipulation of B7-H1 pathway thus aids in the design of new regimens in the treatment of human autoimmune disease and the control of malignant cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

Abbreviations

B7-H1 :

B7-homolog 1

CTL :

Cytolytic T cells

IL :

Interleukin

mAb :

Monoclonal antibody

PD :

Programmed death

TCR :

T cell receptor

References

  1. Jantzer P, Schendel DJ (1998) Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 58:3078–3086

    CAS  PubMed  Google Scholar 

  2. D'Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P (1998) Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer 78:699–706

    Article  CAS  PubMed  Google Scholar 

  3. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677–685

    CAS  PubMed  Google Scholar 

  4. Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S (2001) T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 21:215–248

    CAS  PubMed  Google Scholar 

  5. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B (2002) Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 23:240–245

    Google Scholar 

  6. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023

    CAS  PubMed  Google Scholar 

  7. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650

    Article  CAS  PubMed  Google Scholar 

  8. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000) Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265–276

    CAS  PubMed  Google Scholar 

  9. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299

    CAS  PubMed  Google Scholar 

  10. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999–1005

    Article  CAS  PubMed  Google Scholar 

  11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998

    Article  CAS  PubMed  Google Scholar 

  12. Dong H, Zhu G, Tamada K, Chen L (1999) B7–H1, a third member of the B7 family, costimulates T-cell proliferation and secretion of interleukin-10. Nat Med 5:1365–1369

    Article  CAS  PubMed  Google Scholar 

  13. Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Ellis J, Bonnefoy JY (1997) CD86 (B7–2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells. J Biol Chem 272:15613–15619

    Article  CAS  PubMed  Google Scholar 

  14. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CL, Chen L (2003) Costimulating aberrant T cell responses by B7–H1 autoantibodies in rheumatoid arthritis. J Clin Invest 111:363–370

    Google Scholar 

  15. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800

    CAS  PubMed  Google Scholar 

  16. Petroff MG, Chen L, Phillips TA, Hunt JS (2002) B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta [Suppl A]:S95–101

  17. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034

    Article  CAS  PubMed  Google Scholar 

  18. Mazanet MM, Hughes CC (2002) B7–H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169:3581–3588

    CAS  PubMed  Google Scholar 

  19. Tamura H, Dong H, Zhu G, Sica GL, Flies DB, Tamada K, Chen L (2001) B7–H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97:1809–1816

    Article  CAS  PubMed  Google Scholar 

  20. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T (2002) Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptorPD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 84:57–62

    Article  CAS  PubMed  Google Scholar 

  21. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538–5545

    CAS  PubMed  Google Scholar 

  22. Bleul CC, Boehm T (2001) Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product. Eur J Immunol 31:2497–2503

    Article  CAS  PubMed  Google Scholar 

  23. Gray CP, Arosio P, Hersey P (2002) Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 99:3326–3334

    Article  CAS  PubMed  Google Scholar 

  24. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268

    Article  CAS  PubMed  Google Scholar 

  25. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895

    CAS  PubMed  Google Scholar 

  26. Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR, Burrows PD, Billips LG (1997) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 197:177–187

    Article  CAS  PubMed  Google Scholar 

  27. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K (2002) Alarcon-Riquelme ME. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666–669

    Article  CAS  PubMed  Google Scholar 

  28. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T (1996) Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8:773–780

    CAS  PubMed  Google Scholar 

  29. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765–772

    CAS  PubMed  Google Scholar 

  30. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM (2002) PD-1: PD-L inhibitory pathway affects both CD4 (+) and CD8 (+) T cells and is overcome by IL-2. Eur J Immunol 32:634–643

    Article  CAS  PubMed  Google Scholar 

  31. Nishimura H, Minato N, Nakano T, Honjo T (1998) Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 10:1563–1572

    Article  CAS  PubMed  Google Scholar 

  32. Nishimura H, Nose M, Hiai. H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151

    CAS  PubMed  Google Scholar 

  33. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322

    Article  CAS  PubMed  Google Scholar 

  34. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98:13866–13871

    Article  CAS  PubMed  Google Scholar 

  35. Nishimura H, Honjo T, Minato N (2000) Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med 191:891–898

    Article  CAS  PubMed  Google Scholar 

  36. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T (2002) Microanatomical localization of PD-1 in human tonsils. Immunol Lett 83:215–220

    Article  CAS  PubMed  Google Scholar 

  37. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ (2000) How much longer will tumour cells fool the immune system? Immunol Today 21:70–72

    Google Scholar 

  38. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE (1994) B7–1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420–5423

    CAS  PubMed  Google Scholar 

  39. Sykulev Y, Brunmark A, Tsomides TJ, Kageyama S, Jackson M, Peterson PA, Eisen HN (1994) High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc Natl Acad Sci USA 91:11487–11491

    CAS  PubMed  Google Scholar 

  40. Lollini PL, Forni G (1999) Specific and nonspecific immunity in the prevention of spontaneous tumors. Immunol Today 20:347–350

    Google Scholar 

  41. Sinkovics JG, Horvath JC (2000) Vaccination against human cancers. Int J Oncol 16:81–96

    CAS  PubMed  Google Scholar 

  42. Pecher G, Haring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669–673

    Article  CAS  PubMed  Google Scholar 

  43. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854

    Article  CAS  PubMed  Google Scholar 

  44. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE (2002) Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8:343–348

    Article  CAS  PubMed  Google Scholar 

  45. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4–1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682–685

    CAS  PubMed  Google Scholar 

  46. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565–594

    Google Scholar 

  47. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all members in this laboratory for their contribution to the work described in the article. This work was supported by the National Institutes of Health grant CA97085 and by Mayo Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lieping Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dong, H., Chen, L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81, 281–287 (2003). https://doi.org/10.1007/s00109-003-0430-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-003-0430-2

Keywords

Navigation